Talaporfin
|  | |
| Systematic (IUPAC) name | |
|---|---|
| N-{[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-12-ethyl-2,8,13,18-tetramethyl-17-vinyl-2,3-dihydroporphyrin-5-yl]acetyl}-L-aspartic acid | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names | 
| Routes of administration | IV | 
| Legal status | 
 | 
| Identifiers | |
| CAS Number | 110230-98-3   220201-34-3 (sodium salt) | 
| ATC code | none | 
| PubChem | CID 5486799 | 
| ChemSpider | 16737134  | 
| UNII | P4ROX5ELT2  | 
| Chemical data | |
| Formula | C38H41N5O9 | 
| Molar mass | 711.76 g/mol | 
| 
 | |
| 
 | |
|   (what is this?)  (verify) | |
Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT).
It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength.[1]
It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]
It is trademarked as Aptocine by Light Sciences Oncology.[3]
References
- ↑ http://journals.lww.com/jto/Fulltext/2006/06000/Photodynamic_Therapy__PDT__for_Lung_Cancers.18.aspx "Photodynamic Therapy (PDT) for Lung Cancers" 2006
- ↑ http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer" 2006
- ↑ http://www.lsoncology.com/aptocine
| 
 | ||||||||||||||||||||||||||||||||||||||
Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.